Opioid Settlement Results in Agreement to Pay $270M to State of Oklahoma By Makers of Oxycontin

Purdue Pharma, the makers of OxyContin, have agreed to pay $270 million to the state of Oklahoma, resolving claims over its part in the opioid abuse crisis ravaging that state, as well as many others.

Oklahoma Attorney General Mike Hunter issued a press release on March 26, announcing the opioid settlement, which resolves a lawsuit filed against the drug company that was brought by the state.

Lawsuits are currently pending nationwide involving claims brought by a number of states and municipalities, which blame drug manufacturers for creating the nationwide opioid crisis, with Purdue on the frontlines as the creator of OxyContin.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The opioid crisis claims more and more lives each year, due to accidental and intentional overdoses associated with the powerful and addictive pain medications. In fact, Americans are now more likely to die from an opioid overdose than from a car crash.

A report by the U.S. Centers for Disease Control and Prevention published late last year indicated opioids accounted for nearly 70% of all drug overdose deaths.

Oklahoma and other states have accused Purdue Pharma of deceptively marketing OxyContin, Other drug makers, like Johnson & Johnson and Teva Pharmaceuticals, face similar claims. In the press release, Hunter indicated that a trial scheduled for May 28 is still on schedule; just without Purdue’s involvement.

As part of the settlement, Purdue Pharma agrees to establish a nearly $200 million endowment for the Center for Wellness and Recovery at Oklahoma State University, which researches the treatment of pain and drug addiction. The company will also pay the state $60 million to pay for the litigation and will pay $12.5 million in funds that will go directly to cities and counties in Oklahoma to help combat the opioid crisis.

“The addiction crisis facing our state and nation is a clear and present danger,” Attorney General Hunter said in the press release. “Last year alone, out of the more than 3,000 Oklahomans admitted to the hospital for a non-fatal overdose, 80 percent involved a prescription opioid medication. Additionally, nearly 50 percent of Oklahomans who died from a drug overdose in 2018 were attributed to a pharmaceutical drug. Deploying the money from this settlement immediately allows us to decisively treat addiction illness and save lives.”

There are currently more than 1,300 opioid addiction lawsuits filed in the federal court system, each seeking damages from various manufacturers and distributors of the powerful narcotic medications over addiction and abuse problems that have plagued the nation in the recent years.

Given common questions of fact and law raised in the claims, the U.S. JPML established centralized proceedings for the opioid cases last year, consolidating the claims before U.S. District Judge Dan A. Polster in the Northern District of Ohio, for coordinated discovery and pretrial proceedings.

Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.




0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

A new lawsuit against Roblox alleges that the platform’s inadequate safety measures enabled multiple sexual predators to exploit a five-year-old girl.
Breast mesh implants promoted as internal bras are now under scrutiny, following studies and FDA warnings linking the devices to infections, implant loss, and surgical failure. Lawsuits are being investigated for women who suffered complications after reconstruction or augmentation procedures involving products like GalaFLEX, Phasix, Strattice, and AlloDerm.
Dupixent users are coming forward with accounts of devastating cancer diagnoses, saying the popular eczema drug masked early warning signs of cutaneous T-cell lymphoma. As the FDA investigates and the first lawsuit is filed, researchers warn Dupixent may unmask or accelerate hidden cancers, raising urgent questions about its long-term safety.